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Background: Patient-	relevant	health	outcomes	 for	persons	with	hemophilia	 should	
be	identified	and	prioritized	to	optimize	and	individualize	care	for	persons	with	he-
mophilia.	Therefore,	an	international	group	of	persons	with	hemophilia	and	multidis-
ciplinary health care providers set out to identify a globally applicable standard set of 
health outcomes relevant to all individuals with hemophilia.
Methods: A	systematic	 literature	search	was	performed	to	 identify	possible	health	
outcomes	 and	 risk	 adjustment	 variables.	 Persons	 with	 hemophilia	 and	 multidisci-
plinary health care providers were involved in an iterative nominal consensus pro-
cess	to	select	the	most	important	health	outcomes	and	risk	adjustment	variables	for	




























5.0	per	100,000	male	 live	births,	 respectively.1	The	 lack	of	 func-
tional	 coagulation	 factor	 VIII	 or	 IX	 causes	 spontaneous	 bleeding	
in	persons	with	severe	hemophilia,	especially	affecting	 joints	and	




toms usually consistent with mild hemophilia but with a predomi-
nance	of	reproductive	tract	bleeding.	Overall,	treatment	for	severe	
cases consists of intravenous coagulation factor replacement ther-
apy	to	treat	bleeds	(on-	demand	treatment)	or	regular	infusions	to	
prevent	 bleeds	 (prophylaxis).4	 Additional	 treatment	 options	 such	
as	non–	factor-	based	replacement	therapies	have	been	marketed	in	
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recent	years,	and	gene	 therapy	will	become	available	 in	 the	near	
future.4-	6
In	 recent	 decades,	 advances	 in	 hemophilia	 treatment	 have	 re-
sulted	in	a	near-	normal	life	expectancy	and	lower	burden	of	bleeding	





outcomes that matter to patients within available budgets for any 
given medical condition.9 Value is measured at the medical condi-
tion	 level	and	 is	viewed	as	a	ratio	of	patient-	relevant	health	out-
comes achieved and the cost of achieving these outcomes over 
the full cycle of care.9-	11	Selection	of	a	standardized	set	of	well-	
defined	patient-	relevant	health	outcomes	for	a	medical	condition	
such as hemophilia is an essential step toward delivering value by 
enabling monitoring of health outcomes of each individual over 
time.	 Concurrent	 collection	 of	 individual	 patient	 and	 treatment	
characteristics	 is	 required	 for	 risk-	adjusted	 comparisons	 of	 out-
comes between populations.12
The	 value-	based	 health	 care	 framework	 according	 to	 Porter11 
distinguishes	 three	 hierarchically	 ordered	 tiers	 of	 outcomes,	 with	




dimensions	 of	 time	 to	 recovery	 and	 disutility	 of	 care	 (discomfort	
or	 complications),	 and	 tier	 3	 outcomes	 relate	 to	 long-	term	 conse-
quences	of	the	disease	or	treatment.11	Health	care	in	low-	resource	
settings	(eg,	lower-	income	countries,	more	remote	areas	or	hospitals	
without	 a	 hemophilia	 treatment	 center)	may	prioritize	 assessment	
and	 improvement	of	outcomes	 in	 the	higher	 tiers,	while	 care	pro-
viders	in	more	resource-	rich	settings	may	aim	to	improve	outcomes	
in all tiers.
Outcome	 sets	 evolve	over	 time	 and	build	on	earlier	 outcome	
sets.13-	16	The	recently	published	patient-	relevant	outcomes	frame-
work	 for	 hemophilia	 care13	 required	 broader	 validation	 by	 input	








Detailed	 descriptions	 of	 participants,	 literature	 search,	 consensus	
process,	panel	meetings,	and	outcome	measurement	recommenda-
tions	are	documented	in	the	Supporting	Information.
2.1  |  Project overview
A	nominal	 consensus	process	was	 applied	 according	 to	 the	value-	
based	health	care	methodology,18	as	endorsed	by	the	International	
Consortium	for	Health	Outcomes	Measurements	(ICHOM)	and	the	
National	 Health	 Service.19	 In	 a	 parallel	 multistep	 process,	 includ-
ing	multiple	web-	based	meetings,	consensus	was	sought	on	the	el-
ements	 of	 the	 standard	 set:	 (i)	 definition	 of	 the	 patient	 group	 for	
whom	the	 standard	outcomes	 set	 is	 intended,	 that	 is,	 the	medical	
condition;	(ii)	health	outcomes;	and	(iii)	risk-	adjustment	variables.




and	 risk-	adjustment	 variables	 from	 the	 literature	 search;	 earlier	
outcomes initiatives13,14,16,20;	 ICHOM	 standard	 sets19; and clin-
ical	 practice.	 The	 steering	 group	 and	 Patients	 and	 Health	 Care	
Professionals	 Panel	 members	 individually	 voted	 for	 the	 most	
relevant	 health	 outcomes	 and	 risk	 adjustment	 variables	 before	
each	 web-	based	 meeting.	 Voting	 results	 were	 discussed	 during	
the	web-	based	meetings	until	consensus	was	reached.	Consensus	
was	 considered	 reached	when	no	new	 topics	 or	 questions	were	
raised.	The	independent	International	Academic	Council	reviewed	
the	process	and	selection	of	results	(Table	1).	Finally,	the	core	and	
steering group assessed and selected available outcome measure-
ment instruments.
2.2  |  Identification of health outcomes set
1. Definition of the medical condition.	People	included	in	the	medical	
condition	 definition	 have	 similar	 medical	 needs,	 and	 the	 same	
set	 of	 health	 outcomes	 is	 relevant	 to	 them.	 Consensus	 was	
sought	 on	 the	 definition	 of	 the	 medical	 condition,	 including	
patient	inclusion	and	exclusion	criteria,	identification	of	potential	
relevant subgroups for whom distinct additional outcomes are 
needed,	establishment	of	first	and	last	time	points	of	treatment	
by	 hemophilia	 care	 teams,	 and	 available	 treatment	 types.2,9,21




by health care professionals.10	Outcome	selection	was	based	on	the	
degree to which health care activities affect individual health out-
comes,	the	magnitude	of	impact	on	persons	with	hemophilia,	and	
patient numbers for whom health outcomes were relevant.
3. Selection of risk- adjustment variables.	 Risk-	adjustment	 variables	
are patient and treatment characteristics that affect the abso-
lute	 value	 of	 health	 outcomes.	When	 outcomes	 are	 compared	
between	patient	populations	with	different	backgrounds,	adjust-
ment	for	such	characteristics	is	required.
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2.3  |  Recommendations for outcome measurement
For outcomes that can be measured directly from clinical or 
laboratory	 data,	 measurement	 instructions	 were	 described.	 For	
other	outcomes,	hemophilia-	specific	 instruments	and	item	banks	
from	 the	Patient-	Reported	Outcomes	Measurement	 Information	
System	 (PROMIS)22,23 were identified. Selection was primar-
ily based on the fit of the instrument’s contents with the health 
outcome	 to	properly	measure	 the	outcome.	Then,	 selection	was	
based	on	the	(i)	instrument’s	psychometric	quality	(extracted	from	
systematic	 reviews	and	 recent	 literature)15,20,24-	31;	 (ii)	 number	of	
available	 validated	 translations;	 and	 (iii)	 instrument’s	 availability	
and accessibility.
3  |  RESULTS
3.1  |  Literature search
The	literature	search,	based	on	an	earlier	search	strategy	and	long	
list	with	 health	 outcomes	 by	CoreHEM,14 yielded 382 references; 




in	the	 long	 list	used	for	round	1	of	voting	 (Supporting	Information	
and	Table	S5).	In	total,	57	unique	potential	risk-	adjustment	variables	
were	identified	(Table	S7).
Meeting dates Working group Meeting objectives
Jul	19,	2018 Core	and	steering	groupa  –	 Introduce	HaemoValue	project
–	 Value-	Based	Health	Care	education
–	 Define	medical	condition
(1)	Oct	15,	2018 Core	and	steering	group –	 Define	medical	condition	and	patient	group
–	 Discuss	long	list	of	health	outcomes










































TA B L E  1 Overview	of	the	process	of	
standard set development
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3.2  |  Definition of the medical 
condition hemophilia
Consensus	 was	 reached	 on	 the	medical	 condition	 definition	 for	
persons	 with	 hemophilia:	 “All	 people	 (male	 or	 female)	 with	 an	
X-	linked	 congenital	 bleeding	 disorder	 caused	 by	 a	 deficiency	 of	
coagulation	 factor	 VIII	 (hemophilia	 A)	 or	 IX	 (hemophilia	 B)	 with	
plasma	activity	levels	of	factor	VIII/IX	activity	<40	IU/dL.”	The	de-







The	 first	 and	 last	 time	 points	 of	 treatment	 by	 the	 hemophilia	






3.3  |  Health outcomes
Steering group members voted on the long list of 136 health out-
comes	(Table	S5).	Sixty	health	outcomes	were	selected	 in	the	first	
voting	round.	Ten	additional	health	outcomes	were	added	based	on	






outcomes.	 In	 parallel,	 the	 Patients	 and	 Health	 Care	 Professionals	
Panel	 reviewed	 and	 ranked	 15	 of	 the	 45	 health	 outcomes	 as	 the	
most	 important.	Cross	checking	of	these	15	highest-	ranked	health	
outcomes with the short list of 33 health outcomes from the steer-
ing group resulted in 35 outcomes for which the core team drafted 
preliminary	definitions	(Table	S6).	After	combining	similar	outcomes,	
27 outcomes remained on the final short list.
The	final	voting	rounds	by	the	steering	group	and	the	Patients	




included in the final set because it consistently scored higher than 
the	more	broadly	defined	“bleeding	outcomes	(frequency	of	bleed-
ing	episodes/frequency	of	bleeding	episodes	requiring	treatment).”	
However,	 several	 participants	 felt	 that	 a	 more	 broadly	 defined	
bleeding	outcome	 should	 be	 included.	 It	was	 proposed	 to	 replace	
the	outcome	“life-	threatening	bleeding	episodes”	with	the	modified	
outcome	 “severe	 bleeding	 episodes,”	which	 also	 covered	 bleeding	
outcomes	 for	 women.	 After	 discussions	 in	 writing,	 full	 consensus	




(iii)	 ability	 to	engage	 in	normal	daily	activities;	 (iv)	 severe	bleeding	
episodes;	 (v)	number	of	days	 lost	from	school	or	work;	 (vi)	chronic	
pain;	 (vii)	 complications	of	hemophilia	 and	 its	 treatment;	 (viii)	 sus-
tainability	 of	 physical	 functioning;	 (ix)	 social	 functioning;	 and	 (x)	
mental	 health.	 Consensus-	based	 definitions	 of	 each	 of	 the	 health	
outcomes	 are	 listed	 in	 Table	 2,	 including	 the	 type	 of	 reporting	
(clinician-	reported	or	patient-	reported)	 and	 the	 corresponding	do-
main	of	the	International	Classification	of	Functioning	model.32
3.4  |  Risk- adjustment variables
Of	 the	 57	 risk-	adjustment	 variables	 extracted	 from	 the	 literature	
search,	the	steering	group	removed	two	and	added	six	others,	result-
ing	 in	a	 long	 list	of	61	risk-	adjustment	variables	 (Table	S7).	Steering	
group	voting	resulted	in	a	top-	15	list	of	risk-	adjustment	variables.	Six	









care professionals are involved in the management of hemophilia 
(Table	S8).
3.5  |  Recommendations for outcome measurement
Measurement	instructions	were	summarized	for	each	outcome.	The	
outcomes	cure,	impact	of	disease	on	life	expectancy,	severe	bleed-
ing	 episodes,	 number	of	 days	 lost	 from	work	or	 school,	 and	 com-
plications can be assessed directly from clinical or laboratory data. 
Recommended	clinical	instruments,	hemophilia-	specific	instruments	
and	 generic	 PROMIS	 item	banks	 are	 presented	 for	 the	other	 out-
comes	(ability	to	engage	in	daily	activities,	chronic	pain,	sustainabil-
ity	 of	 physical	 functioning,	 social	 functioning,	 and	 mental	 health)	
(Table	3).
Initially,	 a	 total	 of	 25	 potential	 outcome	 measurement	 instru-
ments	 were	 identified	 for	 adults	 (six	 hemophilia-	specific	 instru-
ments,	11	PROMIS	 item	banks,	and	eight	clinical	 instruments)	and	
26	 instruments	 for	 children	 (six	 hemophilia-	specific	 instruments,	
12	PROMIS	 item	banks,	 and	eight	clinical	 instruments).	Scoring	of	
instruments led to the selection of the recommended outcome mea-
surement	instruments	(Tables	S3	and	S9).









ple,	 depending	 on	 language	 and	 availability	 of	 clinical	 or	 research	
staff.	Where	possible,	measurement	of	outcomes	should	be	embed-
ded into routine clinical care.
4  |  DISCUSSION
We	present	a	standard	set	of	health	outcomes	for	all	persons	with	
hemophilia that can be used by hemophilia treatment centers and 
health systems to assess the value provided for persons with hemo-
philia	in	different	geographic	and	health	care	settings.	The	standard	
set was developed by persons with hemophilia and their repre-
sentatives and international panels of health care professionals with 
expertise	across	various	disciplines.	We	propose	appropriate	meas-
urement instruments with the best content fit and the best reported 
psychometric properties.
This	 work	 was	 performed	 in	 close	 collaboration	 with	 earlier	
working	 groups:	 the	 CoreHEM	 core	 outcomes	 set	 for	 hemophilia	
gene therapy trials14;	the	Patient	Reported	Outcomes,	Burdens,	and	
Experiences	 (PROBE)	 study20;	 the	 Cost	 of	 Hemophilia	 in	 Europe:	
a Socioeconomic Survey33;	 the	 Value	 Framework13; core out-
comes set for clinical research in hemophilia34; the Scientific and 
Standardization	 Committee/International	 Society	 on	 Thrombosis	
and	 Haemostasis	 definitions	 in	 hemophilia	 project	 group,2	 an	 ex-





arching goal of health care delivery.9	Without	focus	on	value,	limited	





irrelevant to persons with hemophilia in their daily lives.11	Moreover,	
lack	of	focus	on	value	fails	to	provide	insight	into	the	level	of	patient-	
relevant	 outcomes	 achieved	 and	 sustained	 through	 individualized	
tailoring	of	treatment.	For	most	conditions	treated	through	a	value-	
based	system,	a	focus	on	achieving	outcomes	will	eventually	reduce	
costs because health care activities that do not contribute to better 
outcomes are eliminated.11
In	 high-	income	 countries,	 up	 to	 99%	of	measured	 total	 health	
care costs for severe hemophilia are currently attributed to coag-
ulation factor replacement therapy.33	As	 a	 result,	 decision	makers	
tend	 to	 focus	on	a	per-	unit	or	per-	patient	 cost	 for	product.	There	
is no tabulation of the overall cost to the health care budget or to 
society	long	term	(ie,	surgeries,	hospital	admissions,	unemployment)	
of	 achieving	 the	 current	 outcomes.	 In	 spite	 of	 this,	 over	 the	 past	
20 years most payers have agreed to increased and widespread use 
of	 coagulation	 factor	prophylaxis	 in	 all	 age	groups	 through	 recog-
nition	of	 its	 long-	term	beneficial	outcomes.	These	benefits	 include	
reducing bleeding complications with the prevention or slowing of 
disability	and	enhancing	labor	market	participation.	Still,	the	relative	
F I G U R E  1 International	set	of	
health	outcomes	for	hemophilia.	Health	
outcomes	are	listed	as	a	hierarchy,	with	
the most important health outcomes in 
tier 1
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system cost saved by avoiding poor health outcomes remains un-
measured.	Measuring	the	relative	value	of	therapies	by	comparing	
outcomes	relevant	to	persons	with	hemophilia,	rather	than	relative	
costs	 through	consumption	of	products,	 is	urgently	needed	 in	 the	
light	 of	 recently	 developed	 non–	factor-	based	 therapies	 and	 gene	
therapy,	which	will	affect	coagulation	factor	use	and	be	priced	sim-
ilarly high or higher.
4.1  |  Strengths and limitations





TA B L E  2 Health	outcomes	and	definitions






not include: eliminating transmission of hemophilia to children or fully 
reverting established damage.
Clinician-	reported Body function and 
structures
2.	Impact	of	




Clinician-	reported Body function and 
structures
3.	Ability	to	engage	































acute bleeding episode and may have different causes.
Patient-	reported Body function and 
structures
7.	Complications Any	clinician-	reported	health	complication,	caused	by	the	condition	






orthopedic interventions and physiotherapy.
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TA B L E  3 Measurement	instructions	and	instruments	for	the	health	outcomes	set
Health outcome What to measure
Recommended measurement instruments
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taken	to	include	a	variety	of	persons	with	hemophilia	in	the	Patients	
and	 Health	 Care	 Professionals	 Panel,	 including	 individuals	 with	
hemophilia	 A	 and	 B,	 different	 severities,	 symptomatic	 carriers	 of	
hemophilia,	 and	 parents	 of	 children	with	 hemophilia	 from	 various	
geographic	backgrounds.	Furthermore,	since	the	standard	outcomes	
set needs to be applicable in health care settings with varying re-
sources,	 participants	 represented	 high-	income	 countries,	 upper-	
middle-	income	 countries,	 and	 one	 lower-	middle-	income	 country.	
Since we aimed to identify health outcomes relevant to persons with 
hemophilia,	we	did	not	 involve	policy	makers	 and	payers	 to	 avoid	
bias in the selection of the outcomes.
A	 limitation	of	 this	work	 is	 that	 some	 (sub)groups	of	persons	
with	hemophilia	may	be	underrepresented.	We	attempted	to	reach	





received	 less	 attention,	 as	women	 and	 children	with	 hemophilia	





hemophilia were not included but represented by others in the 
working	groups.	Some	outcomes,	notably	 those	 in	 tiers	1	and	2,	
Health outcome What to measure
Recommended measurement instruments
Hemophilia- specific PROMIS item bank


































Note: For the measurement of the standard set of outcomes we recommend to use the listed hemophilia specific outcome measurement instruments 
or	PROMIS	item	banks.	In	resource-	limited	settings,	health	care	providers	may	start	measuring	outcomes	(in	tier	1).	Based	on	feasibility	and	





















TA B L E  3 (Continued)
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may be less relevant for persons with mild hemophilia than out-
comes	 in	 tier	3.	 In	 future	 revisions	of	 the	outcomes	 set,	we	will	
aim	for	a	more	extensive	representation	of	women,	children,	and	
individuals with mild hemophilia in order to ensure relevance of 
the	outcomes.	The	majority	of	persons	with	hemophilia	and	their	
representatives	 in	 the	 steering	 group	 and	 Patients	 and	 Health	
Care	 Professionals	 Panel	 were	 active	 members	 of	 regional,	 na-
tional,	and	global	patient	organizations.	Their	expertise	may	have	
led	 to	different	opinions	 than	expressed	by	an	 “average”	person	
with	hemophilia.	Even	though	participants	were	instructed	to	rep-




necessary for participation in assignments and discussions during 
web-	based	meetings.	For	these	reasons,	relevance	of	the	set	to	all	
persons with hemophilia around the world will need to be further 
evaluated in practice.
It	 is	 also	 acknowledged	 that	 some	 of	 the	 recommended	
hemophilia-	specific	 outcome	measurement	 instruments	 still	 need	
further	validation,	particularly	in	the	areas	of	structural	validity	(ie,	
the	degree	 to	which	 the	scores	of	an	 instrument	are	an	adequate	
reflection of the dimensionality of the construct35),	responsiveness	
(ie,	the	ability	of	an	instrument	to	detect	change	over	time35),	and	
cross-	cultural	validity.24-	26,36,37	It	 is	important	to	note	that	the	use	
of	 patient-	reported	 outcomes	measures	 (PROMs)	may	 have	 some	
limitations.	First,	PROMs	(including	digital	PROMs)	may	be	less	fea-
sible	in	settings	with	high	functional	illiteracy	rates.	Second,	PROMs	
that	 have	 been	 developed	 in	 high-	income	 countries	 may	 not	 be	
culturally	 appropriate	 for	 lower-	income	 countries	 and	 vice-	versa.	
Cross-	cultural	 adaptation	 is	 essential	 to	 safeguard	 performance.	
Several	 items	 in	 the	 Hemophilia	 Activities	 List	 (HAL),	 for	 exam-
ple,	 are	 not	 applicable	 in	 India	 and	 Jamaica,	while	 the	 Functional	
Independence	Score	in	Hemophilia	(FISH),	an	instrument	developed	
in	 India,	 performs	well	 in	 these	 countries.38,39	 Similarly,	 the	 FISH	
shows ceiling effects and fails to detect early changes in joint health 
in	high-	income	countries	with	early	prophylaxis.40	Health	care	or-
ganizations	may	choose	the	tool	that	 is	most	appropriate	and	fea-
sible	 in	 their	 situation.	 Third,	 PROMs	 are	 subjective	 by	 definition	
and may demonstrate response shift if used to assess changes over 






for parents or guardians completing an instrument for children with 
hemophilia.	 The	 length	 and	 unknown	 responsiveness	 of	 current	
hemophilia-	specific	outcome	assessment	instruments	may	hamper	
their usefulness in clinical practice.
We	selected	relevant	PROMIS	 item	banks22 because they may 
in	 part	 solve	 these	 issues.	 PROMIS	 item	 banks	 have	 been	 devel-
oped	for	many	patient-	relevant	outcomes	and	have	been	validated	
in	diseased	and	healthy	populations.	PROMIS	item	banks	are	avail-
able in many languages and offer greater precision of outcome as-
sessment	 than	 other	 generic	 instruments.	 Since	 item	 banks	 were	
developed	based	on	modern	Item	Response	Theory,	they	allow	for	
selecting	any	number	of	items	from	the	bank	to	produce	a	short	form	




use in hemophilia populations.





tings and patient groups should be evaluated in annual meetings in 
which	health	care	providers	exchange	their	experiences	with	using	
the standard set.
It	 may	 not	 be	 feasible	 or	 necessary	 to	 measure	 the	 complete	
outcomes	set	at	once.	When	time	or	resources	are	limited,	we	en-
courage users of the outcomes set to start with regular assessments 
of	the	outcomes	in	tier	1.	Data	collection	may	be	expanded	to	the	
health outcomes in tiers 2 and 3 at a later stage.
Feasibility of implementation in different healthcare systems 
was	 our	 foremost	 priority.	 Therefore,	 we	 recommend	 the	 use	 of	
widely accepted measurement instruments that are publicly avail-
able in multiple languages and can be administered during routine 
clinical	 practice.	We	 have	 summarized	 the	 length	 of	 each	 instru-
ment,	availability	and	validity	in	multiple	languages,	and	accessibility	
(Table	S9)	to	assist	with	implementation.
National	 registries	 already	 collect	 outcome	 data	 on	 a	 reg-
ular	 basis.	 The	World	 Bleeding	Disorders	 Registry	 of	 the	World	
Federation	 of	 Hemophilia	 promotes	 standardized	 patient	 data	
collection from treatment centers around the world43 and may 
be	used	to	start	measuring	health	outcomes	and	risk-	adjustment	
variables.	An	acceptable	burden	of	outcome	assessments	for	both	
persons with hemophilia and health care providers is crucial for a 
broad	acceptability	and	use	of	any	standard	set.	We	expect	that	
e-	health	 developments	 such	 as	 a	 PROMs	mobile	 app	 or	 routine	
data collection from electronic medical records will greatly re-
duce the burden for both persons with hemophilia and health care 
providers.
4.3  |  Future directions
Hemophilia	care	is	in	transition.	Novel	and	potentially	curative	treat-
ments will be increasingly available for persons with hemophilia in 
the	near	future.	This	may	have	implications	for	the	definition	of	he-
mophilia	(eg,	cutoff	points	for	baseline	coagulation	factor	levels44)	as	
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well	as	for	which	health	outcomes	are	the	most	relevant.	Therefore,	
the currently presented definitions of the medical condition and 
health outcomes may need to be adapted in the future.
In	 addition,	 outcome	 measurement	 instruments	 must	 be	 con-
tinuously	 improved	 and	 adapted	 to	health	 care	developments.	An	
enhanced	version	of	the	FISH	(A.	Srivastava,	personal	communica-
tion)	 is	aimed	at	reducing	the	ceiling	effects	that	have	been	found	
for children and individuals with mild hemophilia.24	 Similarly,	 the	
Hemophilia	Joint	Health	Score	is	currently	under	revision	to	enhance	
efficacy45 and to further improve convergent and discriminant valid-
ity in adults.46	PROBE	is	expanding	country	and	language	availability,	
implementing longitudinal data collection to improve detection of 
change over time and testing performance in new hemophilia pop-
ulations.47	It	may	be	more	contemporary	than	existing	instruments,	
potentially	 replacing	 older	 instruments	 over	 time.	 Finally,	 PROMs	
such	as	the	Canadian	Hemophilia	Outcomes–	Kids’	Life	Assessment	
Tool	questionnaire	are	currently	updated	to	increase	sensitivity	for	
detecting improvements in treatment burden of novel treatments 
and	 to	 include	outcomes	 that	may	become	 relevant	 in	 the	 future,	
such as caregiver and family burden.48
For	all	these	reasons,	we	emphasize	that	the	recommendations	
regarding the standard set of health outcomes and measurement in-
struments are dynamic entities and that revisions should be sched-
uled biennially.
5  |  CONCLUSION
The	presented	 international	 standard	 set	 of	 health	 outcomes	 that	
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